Meeting
2017 ASCO Annual Meeting
High-dose chemotherapy (HDCT) plus peripheral-blood stem-cell transplant (PBSCT) for patients (pts) with relapsed germ-cell tumors (GCT) and active brain metastases (mets).
Authors
Maitri Kalra
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Maitri Kalra , Nabil Adra , John Mckay , Rafat Abonour , Nasser H. Hanna , Lawrence H. Einhorn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Germ Cell/Testicular
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4558)
DOI
10.1200/JCO.2017.35.15_suppl.4558
Abstract #
4558
Poster Bd #
236
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT).
First Author: Fadi Taza
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2024 ASCO Genitourinary Cancers Symposium
High doses of chemotherapy and autologous hematopoietic stem cell transplantation in patients with relapsed/refractory testicular germ cell tumors: Multicenter real-world experience in Argentina.
First Author: Federico Losco
Poster
2017 ASCO Annual Meeting
Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
First Author: Yago Nieto